Tune Therapeutics
About:
Tune Therapeutics is an epigenetic programming platform for the treatment of disease.
Website: https://tunetx.com
Twitter/X: tunetx_news
Top Investors: New Enterprise Associates, Mission BioCapital, Emerson Collective, Hatteras Venture Partners, Saisei Ventures
Description:
Tune Therapeutics strives to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases.
Total Funding Amount:
$40M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Seattle, Washington, United States
Founded Date:
2020-01-01
Founders:
Akira Matsuno, Charles Gersbach, Fyodor Urnov
Number of Employees:
51-100
Last Funding Date:
2021-12-02
IPO Status:
Private
Industries:
© 2025 bioDAO.ai